Jezrael Revalde

Senior Scientist

University of California, San Francisco
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

The main protease (M Pro ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a validated drug target. Starting with a lead-like dihydrouracil chemotype identified in a large-library docking campaign, we improved M Pro inhibition >1000-fold by engaging additional M Pro subsites and using a latent electrophile to engage Cys 145 . Advanced leads from this series show pan-coronavirus antiviral activity, low clearance in mice, and for AVI-4773 , a rapid reduction in viral titers >1,000,000 after just three doses. Both compounds are well distributed in mouse tissues, including brain, where concentrations >1000× the 90% effective concentration are observed 8 hours after oral dosing for AVI-4773 . AVI-4516 shows minimal inhibition of major cytochrome P450s and human proteases. AVI-4516 also exhibits synergy with the RNA-dependent RNA polymerase inhibitor, molnupiravir, in cellular infection models. Related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus. The properties of this chemotype are differentiated from existing clinical and preclinical M Pro inhibitors and will advance therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses.

Year:

2025

Molecular glues, small molecules that bind cooperatively at a protein-protein interface, have emerged as powerful modalities for the modulation of protein-protein interactions (PPIs) and “undruggable” targets. The systematic identification of new chemical matter with a molecular glue mechanism of action remains a significant challenge in drug discovery. Here, we present a scaffold hopping approach, using as a starting point our previously developed molecular glues for the native 14-3-3/estrogen receptor alpha (ERα) complex. The novel, computationally designed scaffold is based on the Groebke-Blackburn-Bienaymé multi-component reaction (MCR), leading to drug-like analogs with multiple points of variation, thus enabling the rapid derivatization and optimization of the scaffold. Structure-activity relationships (SAR) are developed using orthogonal biophysical assays, such as intact mass spectrometry, TR-FRET and SPR. Rational structure-guided optimization is facilitated by multiple crystal structures of ternary complexes with the glues, 14-3-3 and phospho-peptides mimicking the highly disordered C-terminus of ERα. Cellular stabilization of 14-3-3/ERα for the most potent analogs is confirmed using a NanoBRET assay with full-length proteins in live cells. Our approach highlights the potential of MCR chemistry, combined with scaffold hopping, to drive the development and optimization of unprecedented molecular glue scaffolds.

Year:

2025

Year:

2024

DDX3X regulates the translation of a subset of human transcripts containing complex 5′ untranslated regions (5′ UTRs). In this study, we developed the helicase activity reporter for translation (HART), which uses DDX3X-sensitive 5′ UTRs to measure DDX3X-mediated translational activity in cells. To directly measure RNA structure in DDX3X-dependent mRNAs, we used SHAPE-MaP to determine the secondary structures present in DDX3X-sensitive 5′ UTRs and then used HART to investigate how sequence alterations influence DDX3X sensitivity. Additionally, we identified residues 38–44 as potential mediators of DDX3X's interaction with the translational machinery. HART revealed that both DDX3X's association with the translational machinery and its helicase activity are required for its function in promoting the translation of DDX3X-sensitive 5′ UTRs. These findings suggest DDX3X plays a crucial role in regulating translation through its interaction with the translational machinery during ribosome scanning and establish the HART reporter as a robust, lentivirally encoded, colorimetric measurement of DDX3X-dependent translation in cells.

Year:

2024

Collaborators (14)

R. Jeffrey Neitz

Professor

University of California, San Francisco

UNITED STATES
View details

Brian K. Shoichet

University of California, San Francisco

UNITED STATES
View details

Rikke S. Møller

University of Southern Denmark

DENMARK
View details

Nevan Krogan

Professor

University of California, San Francisco

UNITED STATES
View details

Michelle R. Arkin

Professor and Department Chair

University of California

UNITED STATES
View details

Luc Brunsveld

Prof. at Eindhoven University of Technology

Eindhoven University of Technology

NETHERLANDS
View details

Christian Ottmann

Eindhoven University of Technology

NETHERLANDS
View details

Taha Taha

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Adam Renslo

Professor

University of California, San Francisco

UNITED STATES
View details

Markella Konstantinidou

University of California, San Francisco

UNITED STATES
View details

Charles S. Craik

Professor

University of California, San Francisco

UNITED STATES
View details

Melanie Ott

Professor

University of California, San Francisco

UNITED STATES
View details

Stephan Sanders

Professor of Paediatric Neurogenetics

University of Oxford

UNITED KINGDOM
View details

Judd Hultquist

Assistant Professor

Northwestern University

UNITED STATES
View details